Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Deseret News Utah Index
Deseret News Composite
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Astrazeneca Plc ADR
(NQ:
AZN
)
77.62
-0.56 (-0.72%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
3,172,408
Open
78.07
Bid (Size)
77.50 (1)
Ask (Size)
78.75 (1)
Prev. Close
78.18
Today's Range
77.61 - 78.22
52wk Range
60.47 - 87.67
Shares Outstanding
N/A
Dividend Yield
1.20%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Top Stock Reports For Toyota, AstraZeneca & Chubb
September 26, 2024
Today's Research Daily features new research reports on 16 major stocks, including Toyota Motor Corp., AstraZeneca PLC, and Chubb Ltd., as well as two micro-cap stocks Air T, Inc. and Preformed Line...
Via
Talk Markets
AstraZeneca's Top-Selling Cancer Drug Tagrisso Receives FDA Green Light For Another Lung Cancer Indication
September 26, 2024
The FDA has approved AstraZeneca's Tagrisso for treating unresectable, Stage III EGFR-mutated non-small cell lung cancer, showcasing significant improvements in progression-free survival rates.
Via
Benzinga
Exposures
Product Safety
Performance
YTD
+13.48%
+13.48%
1 Month
-11.00%
-11.00%
3 Month
-0.72%
-0.72%
6 Month
+14.57%
+14.57%
1 Year
+14.25%
+14.25%
More News
Read More
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing
September 26, 2024
From
Virtual Investor Conferences
Via
GlobeNewswire
TAGRISSO® (osimertinib) approved in the US for patients with unresectable, Stage III EGFR-mutated lung cancer
September 26, 2024
From
AstraZeneca
Via
Business Wire
Black Diamond Therapeutics' Lead Drug Candidate Shows Initial Anti-tumor Activity In Certain Type Of Lung Cancer Resistant To AstraZeneca's Drug
September 23, 2024
Via
Benzinga
AstraZeneca Dips On Surprise Miss For Gilead-Rivaling Cancer Drug
September 23, 2024
Via
Investor's Business Daily
Latest Trial Setback For AstraZeneca's Dato-DXd, The Drug Fails To Extend Lives Of Pretreated Breast Cancer Patients
September 23, 2024
Via
Benzinga
Datopotamab deruxtecan final overall survival results reported in patients with metastatic HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial
September 23, 2024
From
AstraZeneca
Via
Business Wire
FLUMIST approved for self-administration in the US
September 20, 2024
From
AstraZeneca
Via
Business Wire
2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure?
September 19, 2024
Via
Investor's Business Daily
2 Unstoppable S&P 500 Dividend Stocks to Buy Before They Beat the Market Again
September 19, 2024
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
Chinese Biotech BeiGene Labeled 'Unique Investment' As Analyst Confident In Lead Cancer Drug
September 18, 2024
Via
Benzinga
AstraZeneca's Asthma Drug Gets FDA Approval For Rare Disease Of Blood Vessel Inflammation
September 18, 2024
Via
Benzinga
Exposures
Product Safety
FASENRA approved in the US for eosinophilic granulomatosis with polyangiitis
September 18, 2024
From
AstraZeneca
Via
Business Wire
5 Oversold Stocks to Buy Right Now
September 16, 2024
Via
MarketBeat
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024
September 17, 2024
From
Virtual Investor Conferences
Via
GlobeNewswire
IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) demonstrated unprecedented overall survival in advanced liver cancer with one in five patients surviving five years in HIMALAYA Phase III trial
September 16, 2024
From
AstraZeneca
Via
Business Wire
IMFINZI® (durvalumab) perioperative regimen reduced the risk of recurrence by 32% and the risk of death by 25% vs. neoadjuvant chemotherapy alone in muscle-invasive bladder cancer in the NIAGARA Phase III trial
September 15, 2024
From
AstraZeneca
Via
Business Wire
Time To Invest And Or Trade In Bio-Tech Stocks?
September 13, 2024
Via
Talk Markets
Topics
ETFs
ENHERTU® (fam-trastuzumab deruxtecan-nxki) showed substantial clinical activity in patients with HER2-positive metastatic breast cancer and brain metastases
September 13, 2024
From
AstraZeneca
Via
Business Wire
Moderna To Slash $1.1 Billion From R&D Spending In Major Commercial Push
September 12, 2024
Via
Investor's Business Daily
AstraZeneca CEO Pascal Soriot Updates On Chinese Compliance Probe And Lung Cancer Drug Trial Results
September 10, 2024
Via
Benzinga
AstraZeneca's Investigational Cancer Drug Disappoints In Late-Stage Lung Cancer Trial
September 10, 2024
Via
Benzinga
Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst
September 09, 2024
Via
Benzinga
Datopotamab deruxtecan showed median overall survival of 14.6 months in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial
September 09, 2024
From
AstraZeneca
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.